Aquestive Therapeutics Inc (AQST) Stock Price, Quote & News

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 941 1900

Website: www.aquestive.com

Address:

30 Technology Drive, Warren, United States

drose0527 Oct. 27 at 8:59 PM

$AQST love the fact this has touched or closed no lower than 6.82-6.84. Showing a very strong floor build here the last 4 trading sessions. It’s only a matter of days before we make a run back towards 8 if not higher! Cooling the RSI helps and who knows maybe 6.82 is the new .66 cents floor and this baby runs to 68 upon approval. I mean considering that was 10 x .66 puts us at 6.60 who’s to say 6.80 x 10 can’t put us at 68

0 · Reply

Oliver17 Oct. 27 at 8:43 PM

$AQST Question out there to anyone?? What do you all think of the short % rising? Cramer's following shorting or more institutional digging their heels in the sand?

1 · Reply

LiquidThetaOptions Oct. 27 at 8:18 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AQST Current Share Price: $6.96 Contracts: $AQST May 15, 2026 $7 Calls Scale in: $1.97- $2.41 Scale out: $3.07-$3.94 Can Easily Capture: 60% ROI Blended DTE: 200 Days | Join Elites here: https://liquidtheta.com

0 · Reply

ConfidencePotato Oct. 27 at 7:50 PM

$AQST $KURA 7 eleven 😉

0 · Reply

BigGainTom Oct. 27 at 6:30 PM

$AQST close around 7.10 to complete the 5 day cup and handle.

0 · Reply

Rock6Times Oct. 27 at 5:41 PM

$AQST very atrong pipeline = biyout bait.

0 · Reply

Acemaker12 Oct. 27 at 5:09 PM

$AQST Link to epinephrine 101 talk: https://www.buzzsprout.com/848314/episodes/18019217

0 · Reply

Stone52 Oct. 27 at 4:20 PM

$AQST $SPRY $NVS $RNA M&A in the biotech space continues to heat up as Novartis is buying U.S. biotech firm Avidity Biosciences for about $12 billion in cash - announced this morning. Neither AQST or SPRY will be stand-alone companies at some point.

1 · Reply

UnderLion16 Oct. 27 at 4:19 PM

$AQST https://www.linkedin.com/posts/faact-food-allergy-%26-anaphylaxis-connection-team_sponsored-faactsroundtable-podcast-activity-7388545270264885249-9v4R?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo

0 · Reply

NCpilot172 Oct. 27 at 4:08 PM

$AQST Could see a correction on er, especially with all the Cramer followers. Expecting a disappointment in all honesty. Doesn’t take much when you see people coming in here with “what does the clinical data look like? I didn’t even check before I bought” why would anyone buy a stock like this without even knowing what the clinical data for the main value driver (as of right now) looks like?

0 · Reply

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 12, 2025, 2:57 AM EDT - 15 days ago

Aquestive Therapeutics: A Measured Bet

Oct 8, 2025, 7:00 AM EDT - 19 days ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Sep 5, 2025, 12:40 PM EDT - 7 weeks ago

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

Aug 14, 2025, 6:28 AM EDT - 2 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aug 14, 2025, 6:00 AM EDT - 2 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aug 12, 2025, 10:19 AM EDT - 2 months ago

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Jul 15, 2025, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 25, 2025, 8:03 AM EDT - 4 months ago

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval

Jun 25, 2025, 7:00 AM EDT - 4 months ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

Jun 8, 2025, 11:00 PM EDT - 5 months ago

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

May 13, 2025, 11:35 AM EDT - 5 months ago

Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 6 months ago

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 4:32 PM EDT - 6 months ago

Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential

May 1, 2025, 7:00 AM EDT - 6 months ago

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Apr 9, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Mar 25, 2025, 8:35 AM EDT - 7 months ago

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

Mar 6, 2025, 12:25 PM EST - 8 months ago

Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 4:01 PM EST - 8 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 7:00 AM EST - 9 months ago

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Jan 6, 2025, 12:13 AM EST - 10 months ago

Aquestive Therapeutics: Five Foci For 2025

Nov 9, 2024, 8:00 AM EST - 1 year ago

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +

ABG GSAT WLKP XMTR

Nov 5, 2024, 3:57 PM EST - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 2:09 PM EST - 1 year ago

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 4, 2024, 4:36 PM EST - 1 year ago

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 27, 2024, 8:30 AM EDT - 1 year ago

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Sep 9, 2024, 8:15 AM EDT - 1 year ago

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

Aug 22, 2024, 11:37 PM EDT - 1 year ago

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 20, 2024, 4:12 AM EDT - 1 year ago

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 7, 2024, 2:37 PM EDT - 1 year ago

Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:22 PM EDT - 1 year ago

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

May 9, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 8, 2024, 12:32 PM EDT - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:19 PM EDT - 1 year ago

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 12, 2024, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Apr 9, 2024, 1:25 AM EDT - 1 year ago

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

Mar 19, 2024, 9:49 PM EDT - 1 year ago

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Mar 14, 2024, 5:23 PM EDT - 1 year ago

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Mar 6, 2024, 10:11 AM EST - 1 year ago

Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 5:05 PM EST - 1 year ago

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Feb 21, 2024, 8:00 AM EST - 1 year ago

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

drose0527 Oct. 27 at 8:59 PM

0 · Reply

Oliver17 Oct. 27 at 8:43 PM

$AQST Question out there to anyone?? What do you all think of the short % rising? Cramer's following shorting or more institutional digging their heels in the sand?

1 · Reply

LiquidThetaOptions Oct. 27 at 8:18 PM

0 · Reply

ConfidencePotato Oct. 27 at 7:50 PM

$AQST $KURA 7 eleven 😉

0 · Reply

BigGainTom Oct. 27 at 6:30 PM

$AQST close around 7.10 to complete the 5 day cup and handle.

0 · Reply

Rock6Times Oct. 27 at 5:41 PM

$AQST very atrong pipeline = biyout bait.

0 · Reply

Acemaker12 Oct. 27 at 5:09 PM

$AQST Link to epinephrine 101 talk: https://www.buzzsprout.com/848314/episodes/18019217

0 · Reply

Stone52 Oct. 27 at 4:20 PM

1 · Reply

UnderLion16 Oct. 27 at 4:19 PM

0 · Reply

NCpilot172 Oct. 27 at 4:08 PM

0 · Reply

Ravery Oct. 27 at 3:44 PM

$AQST Shorts digging their heels in. SI hit a new 52 week high @ 12.25 M shares as of 10/15. It was 8.88M a month earlier. The Cramer pump was not short covering.

1 · Reply

1ightningscalps Oct. 27 at 3:01 PM

1ightning® Options Trade Alert (Actionable) | Buy $AQST Nov 21 $8 Call | Enter: $0.60 Exit: $1.00 | Profit: 66.74% ROI | https://1ightning.com

0 · Reply

Acemaker12 Oct. 27 at 2:24 PM

$AQST

0 · Reply

TIG2 Oct. 27 at 1:59 PM

$AQST Would a out of US partner affect our buy-out prospects ? Maybe that's why nothing yet...

1 · Reply

UnderLion16 Oct. 27 at 1:24 PM

$AQST https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-report-third-quarter-2025-financial

0 · Reply

MoneyGroupLLC Oct. 27 at 5:38 AM

Enter: $AQST Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.60 - $0.75 Sell Price: $0.89 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Dp2424 Oct. 27 at 3:51 AM

$AQST How are we doing folks? $7.50+ tomorrow?

2 · Reply

Biotechnicity Oct. 26 at 3:47 PM

$AQST https://youtu.be/d5LiDs8mKig?si=edJNjs1ETxbPXnM9 Of course we all feel it to varying degrees. Some of us have known this for years and been derided by the intelligences remnant on stock message boards. Which is to say, by fookinitliots. See how easy it would be, is, to manipulate the market? It’s done for the hedge funds with short positions locked onto the preselected run-up (Cramer?) price. As trader’s know, the real money is in buying and selling puts. It isn’t to say that Cramer is making a bad pick here. Hopefully, he isn’t! It is to say he makes the wealthy wealthier, the rich richier and so on by providing the necessary cover. Beautiful day today.

1 · Reply

LiquidThetaOptions Oct. 26 at 1:14 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AQST Current Share Price: $6.84 Contracts: $AQST May 15, 2026 $7 Calls Scale in: $2.02- $2.47 Scale out: $3.14-$4.04 Can Easily Capture: 60% ROI Blended DTE: 201 Days | Join Elites here: https://liquidtheta.com

0 · Reply

MoneyGroupLLC Oct. 26 at 9:47 AM

0 · Reply

tedevan Oct. 25 at 9:33 PM

$IOVA $AQST

0 · Reply

drose0527 Oct. 25 at 5:04 PM

$AQST looks like it’s trying to make a run. Even though we are closing in the red we are still having an underlying conviction of buying which tells me that while heads are exchanged we will break to the upper side again and run into the 8’s or maybe even 9 in November. If you do factor in inflation. Again 5 years ago we went from 7-9 in the course of 3 month of Oct-Dec. I think we will make the same move but with bigger up side so we may go 7-9-11 the next three months. Either way we are in count down mode. Stock looks to be very stable in the 6.70 range for a new ground floor. Accumulation seems like it’s still happening just a matter of waiting it out. But I think we could see a move north of 8 in the next 1-2 weeks as November comes crawling in

1 · Reply

Market Cap	682.11M
Revenue (ttm)	57.56M
Net Income (ttm)	-44.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76.69%
Debt to Equity Ratio	-0.44

Volume	2,019,484
Avg Vol	3,213,316
Day's Range	N/A - N/A
Shares Out	99.72M
Stochastic %K	32%
Beta	1.77
Analysts	Strong Sell
Price Target	$9.07